2023 Annual Report

To our valued shareholders:

Rounding Out Year One

As my first year at GoodRx comes to a close, I am both encouraged and energized by the meaningful progress made in 2023. I believe that as we continue to further our mission by helping more Americans find and access affordable healthcare, the stronger this business can become. I'm often asked what surprised me most about GoodRx, and quite honestly, it's how effective the basic value proposition of the Company is and how much consumers and healthcare professionals appreciate what we do. Over the history of the Company, GoodRx has saved consumers approximately $70 billion. In 2023 alone, over 25 million consumers saved approximately $15 billion on their prescriptions using GoodRx. There is big fundamental value here. And while healthcare is highly complex, the role GoodRx plays is pretty simple.

Consumers today are facing rising healthcare costs with plans continuing to increase patient out- of-pocket costs, like deductibles and copays, and increasing gaps in drug coverage with narrower formularies. We believe these market coverage trends are stronger than ever and we don't expect them to change. We believe this reality makes GoodRx an essential part of the American healthcare system as a trusted solution for consumers to access affordable medications in the U.S. Healthcare providers recognize this, which is why we've become a reliable resource for them, and why we estimate that more than 80% of healthcare professionals refer their patients to us1 and over 750,000 healthcare providers visit GoodRx annually.2 We believe our ability to create and deliver value across the ecosystem of consumers, healthcare providers and partners, has allowed us to deepen trust, drive demand and further differentiate our offerings and experiences, making GoodRx one of the leading consumer-driven digital healthcare experiences.

For those who have been following both GoodRx and the industry, short-term rivalry among value chain constituents has been a constant, with pharmacies, PBM's, payers and others acting and reacting to drive their interests and their economics. That hasn't impacted our view of our prospects. We believe the tailwinds are increasing for GoodRx: Patient out-of-pocket costs are growing, making GoodRx savings more relevant to more individuals, and as we've shown with the launch of our Integrated Savings Program B2B offering, to employers and their PBMs. Our scale and our retuto Adjusted Revenue6 growth in the third quarter of 2023 showcase the strength of the GoodRx value proposition, and underscore our confidence in our ability to accelerate our growth trajectory.

Top Priorities for Growth

In 2023, we introduced clear priorities that reinforce our value proposition:

1 Make sure we have the strongest network relationships and retail pharmacy strategy possible.

1. Hone our short- and medium-term growth plans for the core prescription transactions offering and align our teams and resources behind it.
2. Scale our pharma manufacturer solutions efforts.

Fiscal Year 2023 Highlights

~$70B

Saved by consumers cumulatively3

~$15B

Saved by consumers in 20234

25M+

Consumers saved on their prescriptions using GoodRx in 20235

750K+

Unique healthcare providers (HCPs) visit GoodRx annually2

pharmacies, work closely with us to create consumer value while executing against joint revenue and margin targets. We believe this is complementary to our PBM relationships and helps ensure network stability. In the fourth quarter, our contracting efforts with retailers were a driver of topline performance as we continued to sign direct contracts with new pharmacies and expanded the drugs covered by direct contracts within pharmacies. By year-end 2023, we had retail-direct contracts with most of our largest retail pharmacy partners, and our directly contracted medication volume made up a growing minority of our prescription transactions volume.

Our second priority has been to hone our growth plans for our core prescription transactions offering which includes extending the benefit of GoodRx to commercial insurance programs, or 'funded plans'. We've done this through our Integrated Savings Program, or ISP, with PBM partners like CVS Caremark, Express Scripts, MedImpact and Navitus who aggregate demand for our prescription discounts. We are driving real value with payers and their members by seamlessly lowering the cost of their prescriptions automatically at the point of sale. We are quickly becoming a leader in the commercial market for integrated benefits, and while our programs are currently only available to a subset of our partner PBMs' eligible members, these PBMs cover over 60% of eligible U.S. lives7 so the opportunity could be significant. The early traction on this program is encouraging and we look forward to continuing to ramp it over time by working to add more PBMs and types of prescription transactions to the program.

Third, we've been bringing GoodRx savings to brand drugs through our pharma manufacturer solutions offering. In 2023 we prioritized deal quality, with a focus on foregoing one-off deals and instead creating standardized go-to-market programs that we expect to scale sustainably. Our restructuring of this offering, including rationalizing vitaCare, was essentially complete and is expected to drive margin accretion.

Finally, I believe we have a strong management team in place and are organized to execute effectively. During the year, we made two great executive additions, Dorothy Gemmell, as Chief Commercial Officer, and we welcomed Andrew Slutsky back as our new Chief Marketing Officer, and promoted several high-performing executives including Mike Walsh, who is now our President & EVP, Prescription Marketplace to help us execute with speed and quality. Our team has a nice balance of healthcare and consumer internet expertise, a combination that I believe enables us to create elegant experiences for our 25+ million annual consumers and add distinctive value in healthcare.

During 2023, we began to see positive momentum in the business, both financially and operationally. In the third quarter, we returned to growth on an Adjusted Revenue6 basis. In the fourth quarter, Adjusted Revenue6 growth accelerated to 7% year-over-year and we saw increased flow through and margin accretion with our Adjusted EBITDA Margin6 of 29.1%, up 220 basis points year-over-year, with Adjusted EBITDA6 growing 15% year-over-year.

This financial performance is the direct result of our efforts executing against our priorities in 2023. I would like to thank our incredible team of dedicated and passionate employees who helped drive our meaningful progress. I'm confident in our belief that our priorities are the right ones to both deliver growth and contribute to shareholder value creation. I believe if we keep doing impactful things that add value for consumers and reduce friction in the system, we'll both help a ton of people and make GoodRx a better business.

Scott Wagner

Interim CEO

Fiscal Year 2023 Highlights

$760.3M

Adjusted Revenue6

$217.4M

28.6% Adjusted

EBITDA Margin6

$138.3M

Net Cash provided by Operating Activities

K Y U[[fY[UhY aUf_Yh jU iY c h Y jch]b[ UbX bcb)jch]b[ ghcW_ Y X Vm bcb)U fY[]ghfUbhtg acgh fYWYbh m Wcad YhYX gYWcbX ]gWU eiUfhYf( kUg Uddfcl]aUhY m

• ]UhYg c h Y fY[]ghfUbh( Ug c AibY /,( .,./( h Y Ugh Vig]bYgg XUm c h Y 0./*5 a] ]cb*